Protein kinase C inhibitor anchored BRD4 PROTAC PEGylated nanoliposomes for the treatment of vemurafenib-resistant melanoma
Author:
Publisher
Elsevier BV
Subject
Cell Biology
Reference66 articles.
1. Melanoma treatment in review;Domingues;ImmunoTargets Ther.,2018
2. The role of BRAF V600 mutation in melanoma;Ascierto;J. Transl. Med.,2012
3. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;N. Engl. J. Med.,2011
4. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact;Rizos;Clin. Canc. Res.,2014
5. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations;Flaherty;N. Engl. J. Med.,2012
Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. PROTACs in Ovarian Cancer: Current Advancements and Future Perspectives;International Journal of Molecular Sciences;2024-05-07
2. Development and in-depth characterization of BRAFi-resistant melanoma cell lines in vitro and in vivo;Experimental Cell Research;2024-05
3. Cutaneous Melanoma and 486 Human Blood Metabolites: A Mendelian Randomization Study;Aesthetic Plastic Surgery;2024-03-04
4. Lenvatinib-valproic acid self nanoemulsifying preconcentrate for the treatment of liver cancer;Journal of Molecular Liquids;2024-03
5. ASDs of PROTACs: Spray-dried solid dispersions as enabling formulations;International Journal of Pharmaceutics;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3